Polomar Health Services Inc (PMHS)
Polomar Health Services, Inc. is a common stock listing on OTC Markets. The company operates as a retail compounding pharmacy and is based in Los Angeles, California. Through its SlimRx online platform, it connects patients with licensed physicians for weight-loss treatment plans that may include compounded semaglutide combined with vitamin B-12 and/or metformin. The company has also indicated plans to launch PoloMeds, a platform focused on diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction treatments such as inhalable sildenafil. In addition, Polomar Health Services develops dermatological formulations intended for conditions including acne, alopecia areata, basal cell carcinoma, Becker’s nevus, vitiligo, and other skin disorders. It also provides prescription fulfillment services for third-party web-based telehealth platforms.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-PMHS
|
$0.21
|
37.6% Upside
|
Undervalued
|
Not available
|
Not available
|
Weak
|
0.0%
|
November 25, 2026
|
1.8x
|
4.291 M
|
6.349 M
|
12.2%
|
51.2%
|
-57.0
|
-0.1%
|
0.1%
|